
Journal of Medicinal Chemistry p. 625 - 629 (1994)
Update date:2022-07-29
Topics:
Thurieau, Christophe
Simonet, Serge
Paladino, Joseph
Prost, Jean-Francois
Verbeuren, Tony
Fauchere, Jean-Luc
We report on the synthesis and pharmacological properties of a new series of thrombin inhibitors derived from hirudin carboxyl-terminal fragments.Two (arylphosphono)phenylalanines, p-PO3H2-L-Phe1 and m-PO3H2-L-Tyr, and one (carboxymethyl)phenylalanine, p-CH2COOH-L-Phe, were prepared and incorporated into position 63 of the modified hirudin's C-terminal dodecapeptide using the Fmoc solid-phase synthesis strategy.Substitution by any one of the residues led to very active analogs which doubled the thrombin time at low micromolar concentration (Ctt2) in vitro (1 μM < Ctt2 < 3 μM) and potently increased the activated partial thromboplastin time (APTT) ex vivo.These compounds displayed a higher potency in vitro and a longer duration of action in vivo than both the corresponding sulfated or phosphorylated tyrosine counterparts.
View MoreCGeneTech (Suzhou, China) Co., Ltd.
Contact:+86-512-62956962
Address:Room 101,Bld C11,218 Xinghu Rd.,Suzhou industrial Park
Zhushan County Tianxin Pharmaceutical & Chemical Co., Ltd.
Contact:0086-719-4224892
Address:Tutang Road, Chengguan Town, Zhushan County, Hubei Province
Changzhou Anyi Biochem Co., Ltd.(expird)
Contact:+86-519-88836158
Address:no,51 caoda
Tianjin Jiuri New Materials Co., Ltd.
Contact:+86-22-58889220
Address:C-5/6, Vison Hill, No.1 Gonghua Road, Huayuan Hi-tech Park, Tianjin, China.
Shanxi Tongji Pharmaceuticals Co., Ltd.
Contact:+86-359-3024784
Address:Xikuang South Road, Ruicheng County , Shanxi
Doi:10.1016/S0040-4039(00)61619-2
(1993)Doi:10.1002/ejoc.201900450
(2019)Doi:10.1039/C6CC09323J
(2017)Doi:10.1002/hlca.19940770213
(1994)Doi:10.1080/15257779508012405
(1995)Doi:10.1016/0045-6535(94)90008-6
(1994)